Deals and M&A https://www.bioworld.com/rss en-us Regeneron enters radiopharma space via Telix deal http://www.bioworld.com/articles/730422 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730422-regeneron-enters-radiopharma-space-via-telix-deal Open blue capsule with yellow radioactive symbol Everest to acquire Singapore unit of Hasten Bio in $250M deal http://www.bioworld.com/articles/730419 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730419-everest-to-acquire-singapore-unit-of-hasten-bio-in-250m-deal Handshake behind digital globe Biopharma deal value gains 17% in early 2026 http://www.bioworld.com/articles/730417 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730417-biopharma-deal-value-gains-17-in-early-2026 Gold wireframe handshake Avanos Medical to go private in $1.27B acquisition by AIP http://www.bioworld.com/articles/730298 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730298-avanos-medical-to-go-private-in-127b-acquisition-by-aip Acquisition target Abbvie nabs two Nav1.8 pain projects from Haisco in $745M deal http://www.bioworld.com/articles/730297 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730297-abbvie-nabs-two-nav18-pain-projects-from-haisco-in-745m-deal Open capsule delivering pain relief to body Kazia Therapeutics licenses SETDB1 platform from QIMR Berghofer http://www.bioworld.com/articles/730347 Tue, 14 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730347-kazia-therapeutics-licenses-setdb1-platform-from-qimr-berghofer Concept of business partnership Stryker agrees to buy Amplitude Vascular Systems for IVL tech http://www.bioworld.com/articles/730284 Mon, 13 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730284-stryker-agrees-to-buy-amplitude-vascular-systems-for-ivl-tech Pulse IVL intravascular lithotripsy (IVL) platform Pulse IVL intravascular lithotripsy platform. Credit: Amplitude Vascular Systems Inc. Biopharma deal value gains 17% in early 2026 http://www.bioworld.com/articles/730283 Mon, 13 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730283-biopharma-deal-value-gains-17-in-early-2026 Gold wireframe handshake Regeneron enters radiopharma space via Telix deal http://www.bioworld.com/articles/730282 Mon, 13 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730282-regeneron-enters-radiopharma-space-via-telix-deal Open blue capsule with yellow radioactive symbol Revenio speeds up growth acquiring Visionix for €290M http://www.bioworld.com/articles/730279 Mon, 13 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730279-revenio-speeds-up-growth-acquiring-visionix-for-290m Close up of eye and vision test Abbvie licenses ex-China rights to Haisco pain compounds http://www.bioworld.com/articles/730326 Mon, 13 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730326-abbvie-licenses-ex-china-rights-to-haisco-pain-compounds 3D illustration of a nerve cell Everest to acquire Singapore unit of Hasten Bio in $250M deal http://www.bioworld.com/articles/730212 Thu, 09 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730212-everest-to-acquire-singapore-unit-of-hasten-bio-in-250m-deal Handshake behind digital globe C4 yourself: $1B second Roche deal evidence of DAC faith http://www.bioworld.com/articles/730207 Thu, 09 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730207-c4-yourself-1b-second-roche-deal-evidence-of-dac-faith Antibody-drug conjugate Gilead buying Tubulis and its ADCs in $5B takeover bid http://www.bioworld.com/articles/730133 Tue, 07 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730133-gilead-buying-tubulis-and-its-adcs-in-5b-takeover-bid Antibody-drug conjugates floating on light purple background Vykat caveat: Neurocrine’s $2.9B Soleno bid low-ball? http://www.bioworld.com/articles/730115 Mon, 06 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730115-vykat-caveat-neurocrines-29b-soleno-bid-low-ball Vykat XR Credit: Soleno Therapeutics Inc. Blockbuster deals push med-tech M&A above $40B in Q1 2026 http://www.bioworld.com/articles/730075 Thu, 02 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730075-blockbuster-deals-push-med-tech-m-and-a-above-40b-in-q1-2026 M&A cityscape Korsana boosts Alzheimer’s work with reverse merger, $380M financing http://www.bioworld.com/articles/730126 Thu, 02 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730126-korsana-boosts-alzheimers-work-with-reverse-merger-380m-financing Connecting puzzle pieces Korsana boosts Alzheimer’s work with reverse merger, $380M financing http://www.bioworld.com/articles/729977 Wed, 01 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/729977-korsana-boosts-alzheimers-work-with-reverse-merger-380m-financing Connecting puzzle pieces Lilly taps Insilico AI in $2.75B deal to expand pipeline options http://www.bioworld.com/articles/730091 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/730091-lilly-taps-insilico-ai-in-275b-deal-to-expand-pipeline-options Pill in immersive interface Otsuka to acquire PTSD drugmaker Transcend in $1.2B deal http://www.bioworld.com/articles/730090 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/730090-otsuka-to-acquire-ptsd-drugmaker-transcend-in-12b-deal Brain with handshake and cityscape Galapagos enters new era as Lakefront after reshaping Gilead alliance http://www.bioworld.com/articles/729964 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729964-galapagos-enters-new-era-as-lakefront-after-reshaping-gilead-alliance Handshake icon engraved on metal hexagonal background Highly complementary Biogen pays $5.6B; who’s jealous of Apellis? http://www.bioworld.com/articles/729963 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729963-highly-complementary-biogen-pays-56b-whos-jealous-of-apellis Handshake with charts, maps, data Lilly shifts from obesity to narcolepsy with $7.8B Centessa buy http://www.bioworld.com/articles/729962 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729962-lilly-shifts-from-obesity-to-narcolepsy-with-78b-centessa-buy Brain with clock hands, day and night background Otsuka to acquire PTSD drugmaker Transcend in $1.2B deal http://www.bioworld.com/articles/729952 Mon, 30 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729952-otsuka-to-acquire-ptsd-drugmaker-transcend-in-12b-deal Brain with handshake and cityscape Lilly taps Insilico AI in $2.75B deal to expand pipeline options http://www.bioworld.com/articles/729949 Mon, 30 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729949-lilly-taps-insilico-ai-in-275b-deal-to-expand-pipeline-options Pill in immersive interface Novartis buying allergy firm Excellergy for $2B http://www.bioworld.com/articles/729915 Fri, 27 Mar 2026 08:00:00 -0400 https://www.bioworld.com/articles/729915-novartis-buying-allergy-firm-excellergy-for-2b Handshake dollar sign Merck adds Terns’ promising CML drug in $6.7B buyout http://www.bioworld.com/articles/729837 Wed, 25 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729837-merck-adds-terns-promising-cml-drug-in-67b-buyout Acquisition target China’s pharma rise rattles US policymakers http://www.bioworld.com/articles/729830 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729830-chinas-pharma-rise-rattles-us-policymakers China and U.S. flags Gilead pens dual-purpose $2B Ouro M&A deal with Galapagos http://www.bioworld.com/articles/729829 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729829-gilead-pens-dual-purpose-2b-ouro-m-and-a-deal-with-galapagos Hands holding gears With improved technologies, biomarkers, failed drugs may come into their own http://www.bioworld.com/articles/729826 Tue, 24 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729826-with-improved-technologies-biomarkers-failed-drugs-may-come-into-their-own Vials, syringes, and pills